<DOC>
	<DOCNO>NCT00942188</DOCNO>
	<brief_summary>Study evaluate safety , tolerability efficacy LY2189102 patient type 2 diabetes .</brief_summary>
	<brief_title>A Study LY2189102 Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Have Type 2 Diabetes confirm fast Cpeptide level great equal 0.8 ng/ml ) , duration 3 month . Body mass index 25 40 kg/m2 . Stable diet exercise alone , without metformin monotherapy ( stable regimen dose least 8 week ) . Drugna√Øve previous antidiabetic pharmacotherapy use allow ( latter , patient must stop take pharmacotherapy great 12 week prior screen deem appropriate investigator ) . Angiotensin convert enzyme inhibitor , angiotensin II receptor blocker , thiazide diuretic calcium channel blocker permit treatment hypertension proteinuria . Glycated hemoglobin level 7 % 10 % . Baseline Highsensitivity Creactive protein great equal 2mg/L Females childbearing potential ( surgically sterilize menarche 1 year postmenopause ) must test negative pregnancy time enrollment base pregnancy test . Furthermore , sexually active female male participant must agree use 2 reliable method birth control study 3 month follow last dose study drug . Reliable willing make available duration study willing follow study procedure . Current use antidiabetic pharmacotherapy ( except metformin , condition specify Inclusion Criteria ) . Current treatment antiinflammatory drug , include corticosteroid nonsteroidal antiinflammatory drug ( 100mg per day le aspirin allow ) . Within 60 day initial dose study drug , receive treatment drug receive regulatory approval indication . Presence autoantibody glutamic acid decarboxylase 65 isletcell autoantibody2 . Evidence tuberculosis document specific assay , medical history , chest xray . A specific assay , e.g. , tuberculin testing , conduct unless medically inappropriate . Exceptions include patient history positive specific assay TB treat isonicotinyl hydrazine ( document ) least 6 month , patient previous diagnosis TB appropriately treat provide documentation . Symptomatic herpes zoster within 3 month randomization . Show evidence hepatitis C and/or positive hepatitis B surface antigen . Show evidence human immunodeficiency virus and/or positive test antibody HIV . Received live attenuate vaccine ( ) within previous 3 month prior randomization receive within 3 month end study . Screening serum creatinine great 2.0 mg/dL . Serum Asparate aminotransferase Alanine aminotransaminase concentration great 2x upper limit normal . Known allergy LY2189102 excipients . Previously complete withdrawn study study investigate LY2189102 . Have donate blood great 500 mL within precede 30 day intend donate within 3 month end study . Have recent ongoing sign infection ( e.g . fever , current treatment antibiotic ) . Experienced serious bacterial infection within 6 month randomization . Have serious medical illness include limited cardiovascular , hepatic , respiratory , hematological , endocrine , neurological disease , clinically significant laboratory abnormality . Have lymphoma , leukemia , nonbreast malignancy within past 5 year except basal cell squamous epithelial carcinoma skin resect evidence metastatic disease . Have previous reaction biologics , opinion investigator , put patient serious risk .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Type 2 Diabetes</keyword>
</DOC>